CORPORATE OVERVIEW

TOPIGEN is developing several new classes of drugs and is actively progressing two drug candidates in Phase II trials for COPD and asthma. These drugs are uniquely focused on inhibiting multiple inflammation targets underlying the chronic pulmonary diseases. TOPIGEN also has a number of discovery research programs focused on the identification of novel compounds for the treatment of COPD and allergic rhinitis. By applying its knowledge and expertise in respiratory care, along with its proprietary mRNA-based chemistry, TOPIGEN is seeking to make a positive difference for patients.